Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01026493. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with temozolomide may kill more tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of giving veliparib together with temozolomide and to see how well it works in treating patients with recurrent glioblastoma.
Study identification
- NCT ID
- NCT01026493
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 257 participants
Conditions and interventions
Conditions
Interventions
- temozolomide 60 mg x 21 days Drug
- temozolomide 75 mg x 21 days Drug
- ABT-888 20 mg x 21 days Drug
- ABT-888 40 mg x 21 days Drug
- Temozolomide 150 mg x 5 days Drug
- ABT-888 40 mg x 5 days Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2010 (Type not available)
- Primary completion
- May 2014 (Actual)
- Completion
- Dec 2016 (Actual)
- Last update posted
- Jul 2, 2017
2010 – 2016
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rebecca and John Moores UCSD Cancer Center | La Jolla | California | 92093-0658 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Cancer Research Center of Hawaii | Honolulu | Hawaii | 96813 | — |
| Queen's Cancer Institute at Queen's Medical Center | Honolulu | Hawaii | 96813 | — |
| Hawaii Medical Center - East | Honolulu | Hawaii | 96817 | — |
| Leeward Radiation Oncology | ‘Ewa Beach | Hawaii | 96706 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637-1470 | — |
| CCOP - Kansas City | Prairie Village | Kansas | 66208 | — |
| Central Baptist Hospital | Lexington | Kentucky | 40503-9985 | — |
| Louisville Oncology at Norton Cancer Institute - Louisville | Louisville | Kentucky | 40202 | — |
| Regional Cancer Center at Singing River Hospital | Pascagoula | Mississippi | 39581 | — |
| Renown Institute for Cancer at Renown Regional Medical Center | Reno | Nevada | 89502 | — |
| Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756-0002 | — |
| Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08903 | — |
| Highland Hospital of Rochester | Rochester | New York | 14620 | — |
| James P. Wilmot Cancer Center at University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Legacy Good Samaritan Hospital & Comprehensive Cancer Center | Portland | Oregon | 97210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01026493, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2017 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.